Pub Date : 2021-12-20DOI: 10.31031/nacs.2021.06.000645
D. Dix
{"title":"Curing Incurable Cancer","authors":"D. Dix","doi":"10.31031/nacs.2021.06.000645","DOIUrl":"https://doi.org/10.31031/nacs.2021.06.000645","url":null,"abstract":"","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43955571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-16DOI: 10.31031/nacs.2021.06.000644
Ovidiu Farc
{"title":"Implications of Network Biology in the Understanding and Therapy of Cancer","authors":"Ovidiu Farc","doi":"10.31031/nacs.2021.06.000644","DOIUrl":"https://doi.org/10.31031/nacs.2021.06.000644","url":null,"abstract":"","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42176018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-08DOI: 10.31031/nacs.2021.06.000643
O. Bretcanu
Bone is one of the most common sites for metastasis. Approximately 350,000 people die in the United States every year from bone metastases [1]. The most common site of bone metastases is the axial skeleton, with the lumbar region being the most frequently impacted site [2]. Bone cancer can lead to bone pain, hypercalcemia, spinal cord compression and bone fracture, decreasing the quality of life of cancer patients [3]. The most common treatments for bone cancers are surgical resection, radiotherapy and chemotherapy. Hyperthermia is another type of cancer treatment that is generally used for advanced cancers, in combination with radiotherapy or chemotherapy. Clinical trials have shown that hyperthermia reduces the size of tumours, enhancing the effect of radiation or anticancer drugs [4]. Hyperthermia affects both molecular and cellular levels. Alterations to the cytoskeleton and the cell membrane, as well as impairment of protein, Ribonucleic Acid (RNA) and Deoxyribonucleic Acid (DNA) synthesis, inhibition of DNA repair enzymes, altered gene expression and protein denaturation, unfolding and aggregation [5-7] are all changes caused by hyperthermia.
{"title":"Mini Review: Hyperthermia Treatment for Bone Cancers","authors":"O. Bretcanu","doi":"10.31031/nacs.2021.06.000643","DOIUrl":"https://doi.org/10.31031/nacs.2021.06.000643","url":null,"abstract":"Bone is one of the most common sites for metastasis. Approximately 350,000 people die in the United States every year from bone metastases [1]. The most common site of bone metastases is the axial skeleton, with the lumbar region being the most frequently impacted site [2]. Bone cancer can lead to bone pain, hypercalcemia, spinal cord compression and bone fracture, decreasing the quality of life of cancer patients [3]. The most common treatments for bone cancers are surgical resection, radiotherapy and chemotherapy. Hyperthermia is another type of cancer treatment that is generally used for advanced cancers, in combination with radiotherapy or chemotherapy. Clinical trials have shown that hyperthermia reduces the size of tumours, enhancing the effect of radiation or anticancer drugs [4]. Hyperthermia affects both molecular and cellular levels. Alterations to the cytoskeleton and the cell membrane, as well as impairment of protein, Ribonucleic Acid (RNA) and Deoxyribonucleic Acid (DNA) synthesis, inhibition of DNA repair enzymes, altered gene expression and protein denaturation, unfolding and aggregation [5-7] are all changes caused by hyperthermia.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44670821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-30DOI: 10.31031/nacs.2021.06.000641
P. Lissoni
Between the two opposite conditions of curative and palliative therapy of cancer, it has been recently demonstrated the possibility of a third way of treatment, consisting of the administration of natural nontoxic anticancer molecules drawn from the vegetal world or human body itself. At present, the main investigated anticancer natural molecule consists of Melatonin (MLT), which is present in both plants and the human body, where it is mainly released from the pineal gland according to a circadian rhythm, with a high production during night and low levels during the day [1]. In fact, it has been known for more than 50 years that the pineal gland MLT plays an anticancer action. Experimental conditions have shown that pinealectomy enhances the frequency of both spontaneous and carcinogen-induced tumor development. MLT exerts an anticancer action through at least three fundamental mechanisms, consisting of direct antiproliferative cytotoxic action, antiangiogenic activity and stimulation of the anticancer immunity [2], which is mainly mediated by IL-2 [3] and IL-12 [4], and suppressed by TGF-beta [5], IL-17 [6] and other inflammatory cytokines [7]. Studies have demonstrated that MLT is not the only anticancer principle of the pineal gland, since MLT alone has appeared to reduce, but not completely abolish the pro-tumoral effect of pinealectomy [8]. In fact, at least another indole hormone, the 5-Metoxytryptamine (5MTT) [9] and several beta-carbolines, such as 6-methoxy-1,2,3,4-tetra-hydro-beta-carboline, the so-called pinealine [10], have appeared to exert important antitumor activities. However, Abstract
{"title":"Psycho Neuroendocrino Immune (PNEI) Therapy of Cancer Beyond Melatonin","authors":"P. Lissoni","doi":"10.31031/nacs.2021.06.000641","DOIUrl":"https://doi.org/10.31031/nacs.2021.06.000641","url":null,"abstract":"Between the two opposite conditions of curative and palliative therapy of cancer, it has been recently demonstrated the possibility of a third way of treatment, consisting of the administration of natural nontoxic anticancer molecules drawn from the vegetal world or human body itself. At present, the main investigated anticancer natural molecule consists of Melatonin (MLT), which is present in both plants and the human body, where it is mainly released from the pineal gland according to a circadian rhythm, with a high production during night and low levels during the day [1]. In fact, it has been known for more than 50 years that the pineal gland MLT plays an anticancer action. Experimental conditions have shown that pinealectomy enhances the frequency of both spontaneous and carcinogen-induced tumor development. MLT exerts an anticancer action through at least three fundamental mechanisms, consisting of direct antiproliferative cytotoxic action, antiangiogenic activity and stimulation of the anticancer immunity [2], which is mainly mediated by IL-2 [3] and IL-12 [4], and suppressed by TGF-beta [5], IL-17 [6] and other inflammatory cytokines [7]. Studies have demonstrated that MLT is not the only anticancer principle of the pineal gland, since MLT alone has appeared to reduce, but not completely abolish the pro-tumoral effect of pinealectomy [8]. In fact, at least another indole hormone, the 5-Metoxytryptamine (5MTT) [9] and several beta-carbolines, such as 6-methoxy-1,2,3,4-tetra-hydro-beta-carboline, the so-called pinealine [10], have appeared to exert important antitumor activities. However, Abstract","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46054884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-10DOI: 10.31031/nacs.2021.06.000640
S. Alshammary
Palliative care is a specialty of its own consisting of comprehensive multidisciplinary healthcare delivery to patients with a wide range of life-threatening and life-shortening diseases, including cancer. Its primary goal is to relieve symptoms of suffering such as physical pain, psychosocial and spiritual problems that affect the quality-of-life for patients as well as their families. Palliative care has a vital role in providing comfort to patient and family during active interventions like chemotherapy and radiation therapies [1]. The palliative care service in Saudi Arabia started over three decades ago at the King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh by Dr. Isbister [2]. Since then, the specialty has slowly expanded. Real changes came about in 2016 when the Ministry of Health (MOH) launched the Palliative Care/Last Phase Initiative as part of the Transformation of Healthcare Vision 2030 [3]. By 2030, the Cancer care in Saudi Arabia is expected to grow by five to 10-fold. This prediction is defined by the changing demographics, with the age group most affected by cancer being the middle-aged and elderly [1]. The palliative care community in Saudi Arabia saw this as a great opportunity to develop the specialty on a national scale. The process of the development of Palliative Care/ last phase interventions was a long and meticulous one and has been very successful.
{"title":"Development of Palliative Care: The Current Situation in Saudi Arabia","authors":"S. Alshammary","doi":"10.31031/nacs.2021.06.000640","DOIUrl":"https://doi.org/10.31031/nacs.2021.06.000640","url":null,"abstract":"Palliative care is a specialty of its own consisting of comprehensive multidisciplinary healthcare delivery to patients with a wide range of life-threatening and life-shortening diseases, including cancer. Its primary goal is to relieve symptoms of suffering such as physical pain, psychosocial and spiritual problems that affect the quality-of-life for patients as well as their families. Palliative care has a vital role in providing comfort to patient and family during active interventions like chemotherapy and radiation therapies [1]. The palliative care service in Saudi Arabia started over three decades ago at the King Faisal Specialist Hospital and Research Centre (KFSH&RC) in Riyadh by Dr. Isbister [2]. Since then, the specialty has slowly expanded. Real changes came about in 2016 when the Ministry of Health (MOH) launched the Palliative Care/Last Phase Initiative as part of the Transformation of Healthcare Vision 2030 [3]. By 2030, the Cancer care in Saudi Arabia is expected to grow by five to 10-fold. This prediction is defined by the changing demographics, with the age group most affected by cancer being the middle-aged and elderly [1]. The palliative care community in Saudi Arabia saw this as a great opportunity to develop the specialty on a national scale. The process of the development of Palliative Care/ last phase interventions was a long and meticulous one and has been very successful.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48722829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-20DOI: 10.31031/nacs.2021.06.000639
Stephen Brown, J. Snyder, Meser M. Ali
In brain tumors, delivering nanoparticles across the blood-brain tumor barrier presents a major challenge. Dual mode magnetic resonance imaging and fluorescent imaging probes have been developed where relaxation based Gd-DOTA or ParaCEST agents and a Near-Infrared (NIR) fluorescent dye, DL680 were conjugated on the surface of dendrimer. The in vivo and ex vivo imaging of the dual-modality contrast agent showed excellent potential utility for identifying the location of glioma tumors. Systemic delivery of the subsequent nano-sized agent demonstrated glioma-specific accumulation, probably due to the enhanced permeability and retention effect. The biodistribution studies revealed the G5 agents have accumulated in the glioma tumor and the liver while a G3 agent only accumulated in the brain tumor but not in the liver or kidney. Hydrophobic drug molecules like Combrestatin A4 (CA4) or curcumin have also been conjugated with dendrimers that provided high aqueous solubility with improved therapeutic effect.
{"title":"Dendrimer-Based Nanomedicine (Paramagnetic Nanoparticle, Nanocombretastatin, Nanocurcumin) for Glioblastoma Multiforme Imaging and Therapy","authors":"Stephen Brown, J. Snyder, Meser M. Ali","doi":"10.31031/nacs.2021.06.000639","DOIUrl":"https://doi.org/10.31031/nacs.2021.06.000639","url":null,"abstract":"In brain tumors, delivering nanoparticles across the blood-brain tumor barrier presents a major challenge. Dual mode magnetic resonance imaging and fluorescent imaging probes have been developed where relaxation based Gd-DOTA or ParaCEST agents and a Near-Infrared (NIR) fluorescent dye, DL680 were conjugated on the surface of dendrimer. The in vivo and ex vivo imaging of the dual-modality contrast agent showed excellent potential utility for identifying the location of glioma tumors. Systemic delivery of the subsequent nano-sized agent demonstrated glioma-specific accumulation, probably due to the enhanced permeability and retention effect. The biodistribution studies revealed the G5 agents have accumulated in the glioma tumor and the liver while a G3 agent only accumulated in the brain tumor but not in the liver or kidney. Hydrophobic drug molecules like Combrestatin A4 (CA4) or curcumin have also been conjugated with dendrimers that provided high aqueous solubility with improved therapeutic effect.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":"6 1","pages":"609 - 614"},"PeriodicalIF":0.0,"publicationDate":"2021-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47397770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-10-11DOI: 10.31031/nacs.2021.06.000638
Salah Mabrouk Khallaf
Finding the prognostic factors for this dismal disease is still challenging, especially for elderly patients. Patient age [1,2], performance status [1], blood neutrophil-lymphocyte ratio [3], Plasma Chromogranin A [4], frailty index [5] are documented as prognostic factors for outcome of the patients with advanced pancreatic cancer. Data about elderly patients in these trials is limited. We present our practice regarding the importance of frailty index called PRISMA7 (Program of Research to Integrate the Services for the Maintenance of Autonomy-7) score for prognostic stratification of elderly patients with advanced pancreatic cancer. It was highly significant prognostic factor for those patients.
{"title":"Prognostic Value of PRISMA-7 Score for Frail Elderly Patients with Advanced Pancreatic Adenocarcinoma","authors":"Salah Mabrouk Khallaf","doi":"10.31031/nacs.2021.06.000638","DOIUrl":"https://doi.org/10.31031/nacs.2021.06.000638","url":null,"abstract":"Finding the prognostic factors for this dismal disease is still challenging, especially for elderly patients. Patient age [1,2], performance status [1], blood neutrophil-lymphocyte ratio [3], Plasma Chromogranin A [4], frailty index [5] are documented as prognostic factors for outcome of the patients with advanced pancreatic cancer. Data about elderly patients in these trials is limited. We present our practice regarding the importance of frailty index called PRISMA7 (Program of Research to Integrate the Services for the Maintenance of Autonomy-7) score for prognostic stratification of elderly patients with advanced pancreatic cancer. It was highly significant prognostic factor for those patients.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45275616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-08DOI: 10.31031/nacs.2021.06.000635
Yang Xun, Hongping Tang, Y. Pan, D. Shen, Hua Yang, Yijun Liang, Rui-xue Wang, Lixia Fan, Hui Liu, Yilong Ai, Dahai Liu, Fang Liu
Hodgkin’s Lymphoma (HL) is a main type of lymphoma characterized by Hodgkin’s Reed-Sternberg(H/RS) cells, which involves in many cytokines and chemokines. CXC Chemokine Ligand 16 (CXCL16) was reported to be expressed in various cancer types and was previously observed by our group to highly express in H/RS cells, yet the function and mechanism of CXCL16, as well as soluble CXCL16 (sCXCL16) on the phenotypes of HRS cells needs to be fully elucidated. To investigate the effects of CXCL16 on cell proliferation, migration, cell cycle, apoptosis, and immune-phenotypes of H/RS cells, an H/RS cell line (L428) transfected with CXCL16-overexpressed lentivirus vector was established and identified; besides, recombinant sCXCL16 was also applied on L428 cell lines in the present study. Results showed that both endogenously overexpressed CXCL16 and exogenously applied recombinant sCXCL16 protein were able to promote the proliferation and migration of L428 cells, and diminished cell apoptosis, while the immune phenotypes of L428 cells showed no significant changes. Blocking the interaction between the ligand CXCL16 and its unique receptor CXCR6 with antibody suppressed the above effects. As the pathways involved were concerned, results showed that CXCL16 upregulated the expression of several phosphorylated proteins of the PI3K/Akt and NF-κB signaling pathways, which were markedly inhibited by PI3K inhibitor LY294002 or CXCR6 antibody. The present study suggests that CXCL16 promotes the proliferation and migration of H/RS cell through its receptor CXCR6. The mechanism may involve activation of the PI3K/Akt/NF-κB signaling pathways.
{"title":"CXC Chemokine Ligand 16 Promotes the Proliferation and Migration of Hodgkin and Reed-Sternberg Cells Via the PI3K/Akt/NF-κB Signaling Pathway","authors":"Yang Xun, Hongping Tang, Y. Pan, D. Shen, Hua Yang, Yijun Liang, Rui-xue Wang, Lixia Fan, Hui Liu, Yilong Ai, Dahai Liu, Fang Liu","doi":"10.31031/nacs.2021.06.000635","DOIUrl":"https://doi.org/10.31031/nacs.2021.06.000635","url":null,"abstract":"Hodgkin’s Lymphoma (HL) is a main type of lymphoma characterized by Hodgkin’s Reed-Sternberg(H/RS) cells, which involves in many cytokines and chemokines. CXC Chemokine Ligand 16 (CXCL16) was reported to be expressed in various cancer types and was previously observed by our group to highly express in H/RS cells, yet the function and mechanism of CXCL16, as well as soluble CXCL16 (sCXCL16) on the phenotypes of HRS cells needs to be fully elucidated. To investigate the effects of CXCL16 on cell proliferation, migration, cell cycle, apoptosis, and immune-phenotypes of H/RS cells, an H/RS cell line (L428) transfected with CXCL16-overexpressed lentivirus vector was established and identified; besides, recombinant sCXCL16 was also applied on L428 cell lines in the present study. Results showed that both endogenously overexpressed CXCL16 and exogenously applied recombinant sCXCL16 protein were able to promote the proliferation and migration of L428 cells, and diminished cell apoptosis, while the immune phenotypes of L428 cells showed no significant changes. Blocking the interaction between the ligand CXCL16 and its unique receptor CXCR6 with antibody suppressed the above effects. As the pathways involved were concerned, results showed that CXCL16 upregulated the expression of several phosphorylated proteins of the PI3K/Akt and NF-κB signaling pathways, which were markedly inhibited by PI3K inhibitor LY294002 or CXCR6 antibody. The present study suggests that CXCL16 promotes the proliferation and migration of H/RS cell through its receptor CXCR6. The mechanism may involve activation of the PI3K/Akt/NF-κB signaling pathways.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46477937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-18DOI: 10.31031/nacs.2021.06.000634
Hameed Khan
I work on human Brain. The most complex organ in the Universe. I design drugs to treat Brain Cancer. Our Brain is a three-pound flesh that you can hold in the palm of your hand. It can contemplate the vast distances among billions of Galaxies across Universe; It can contemplate the concept of Infinity. It convinces us to believe in existence or non-existence of God. It questions our Ethics; our Morality, our Altruism and our Free-will. It is only a three-pound flesh and yet it can contemplate itself contemplating the meaning of life, asking questions. Questions like; Who are we? Where have we all come from? What was it that made us this way? How this Universe began? Why is it expanding at an accelerating speed? How is it likely to end? Are we alone in the entire Universe or there are other creatures who live in deep dark space of this vast Universe who may or may not look like us?
{"title":"Genomic Medicine: Using Genetic Make-up of the Human Genome, AZQ was Designed to Treat Glioblastoma, the Brain Tumor","authors":"Hameed Khan","doi":"10.31031/nacs.2021.06.000634","DOIUrl":"https://doi.org/10.31031/nacs.2021.06.000634","url":null,"abstract":"I work on human Brain. The most complex organ in the Universe. I design drugs to treat Brain Cancer. Our Brain is a three-pound flesh that you can hold in the palm of your hand. It can contemplate the vast distances among billions of Galaxies across Universe; It can contemplate the concept of Infinity. It convinces us to believe in existence or non-existence of God. It questions our Ethics; our Morality, our Altruism and our Free-will. It is only a three-pound flesh and yet it can contemplate itself contemplating the meaning of life, asking questions. Questions like; Who are we? Where have we all come from? What was it that made us this way? How this Universe began? Why is it expanding at an accelerating speed? How is it likely to end? Are we alone in the entire Universe or there are other creatures who live in deep dark space of this vast Universe who may or may not look like us?","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43664044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：